

Correction: Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer



In the original version of this article (1), Cristina Marchini and Augusto Amici were not properly credited as co-last authors. This error has been corrected in the latest online HTML and PDF versions of the article. The publisher regrets this error.

Reference

1. Bartolacci C, Andreani C, Curcio C, Occhipinti C, Massaccesi L, Giovarelli M, et al. Phage-based anti-HER2 vaccination can circumvent immune tolerance against breast cancer. *Cancer Immunol Res* 2018;6:1486–98.

Published online March 1, 2019.

doi: 10.1158/2326-6066.CIR-19-0085

©2019 American Association for Cancer Research.

Cancer Immunology Research

Correction: Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer

Cancer Immunol Res 2019;7:526.

Updated version Access the most recent version of this article at:
<http://cancerimmunolres.aacrjournals.org/content/7/3/526>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/7/3/526.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/7/3/526>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.